Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05725291 · ClinicalTrials.gov registry record · Phase 1

AMT-116 in Patients With Advanced Solid Tumors

A Phase 1 study of Advanced Solid Tumor, sponsored by Multitude Therapeutics.

Recruiting
Registry status
Phase 1
Development phase
80
Enrollment target
10
Study locations

NCT05725291 is a Phase 1 study of Advanced Solid Tumor that is actively recruiting participants, run by Multitude Therapeutics. The registered enrollment target is 80 participants, below the 193-participant average among 189 other Advanced Solid Tumor trials with a reported enrollment target (59% lower). The trial reports 10 study locations across 8 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05725291, a Phase 1 study of Advanced Solid Tumor, is actively recruiting participants, sponsored by Multitude Therapeutics.

RECRUITING
Registry status
Phase 1
Development phase
80 participants
Enrollment target
10
Study locations

Study Summary

This first-in-human study will evaluate the Maximum Tolerated Dose (MTD) / the Recommended Phase 2 Dose (RP2D), safety, tolerability, anti-tumor activity, pharmacokinetics, pharmacodynamics and immunogenicity of AMT-116, in Patients with Advanced Solid Tumors

Conditions Studied

Advanced Solid Tumor

Interventions

  • DRUG AMT-116

Study Locations (10)

Victoria

  • Alfred Hospital - Victoria Park
  • Austin Health - Victoria Park
  • Cabrini Hospital - Victoria Park

Colorado

  • Sarah Cannon Research Institute - Denver

Texas

  • Mary Crowley Cancer Research Centers - Dallas

California

  • University of California San Francisco Cancer Center - San Francisco

North Carolina

  • Carolina BioOncology Institute, LLC - Cary

New South Wales

  • Macquarie University Hospital - Sydney

Queensland

  • ICON Cancer Centre - Brisbane

South Australia

  • Southern Oncology Clinical Research Unit - Adelaide

Trial Details

FieldValue
Enrollment Target 80 participants
Start Date 2023-07-25
Est. Completion 2026-12-30
Phase Phase 1

Sponsor

Multitude Therapeutics

1 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05725291

The ClinicalTrials.gov registry entry for NCT05725291 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 80 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 193-participant average among 189 other Advanced Solid Tumor trials with a reported enrollment target (59% lower). The listed sponsor is Multitude Therapeutics, which has 1 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Advanced Solid Tumor appearing as the primary indexed condition, and to 1 intervention - of which AMT-116 is the first listed.

NCT05725291 reports 10 study locations spanning 8 distinct geographic areas - top geographies include Victoria, Colorado, Texas.

Frequently Asked Questions

What is clinical trial NCT05725291 about?

NCT05725291 is a clinical study titled "AMT-116 in Patients With Advanced Solid Tumors". This first-in-human study will evaluate the Maximum Tolerated Dose (MTD) / the Recommended Phase 2 Dose (RP2D), safety, tolerability, anti-tumor activity, pharmacokinetics, pharmacodynamics and immunogenicity of AMT-116, in Patients with Advanced Solid Tumors

What is the current status of trial NCT05725291?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 80 participants. The study started on 2023-07-25. Estimated completion is 2026-12-30.

What conditions does trial NCT05725291 study?

This clinical trial studies the following conditions: Advanced Solid Tumor.

What interventions are being tested in trial NCT05725291?

The interventions under investigation include: AMT-116 (DRUG).

Who is sponsoring clinical trial NCT05725291?

This trial is sponsored by Multitude Therapeutics, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05725291 being conducted?

This trial has 10 study locations across Colorado, Texas, California, North Carolina, New South Wales. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Advanced Solid Tumor

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Advanced Solid Tumor

All registered trials for this condition

Colorado

All trials with a study site in Colorado

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.